Mark Staveski

Mark Staveski is a seasoned medical professional with extensive experience in the pharmaceutical industry, currently serving as a Senior Medical Science Liaison at Nurix Therapeutics since June 2025. Mark has held various leadership roles, including Senior Field Medical Director at BeiGene and Medical Science Liaison positions at Oncopeptides AB, Karyopharm Therapeutics Inc., Pharmacyclics (an AbbVie Company), and Infinity Pharmaceuticals. Prior to these positions, Mark contributed as a Medical Science Liaison at Sanofi and Genzyme Corporation, following Genzyme's acquisition by Sanofi in 2011. Mark holds a Master’s Degree in Chemistry from Northeastern University and a Bachelor’s Degree in Chemistry from the University at Buffalo.